Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Mar;39(3):735–738. doi: 10.1128/AAC.39.3.735

Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity.

Y Cohen 1, C Perronne 1, T Lazard 1, C Truffot-Pernot 1, J Grosset 1, J L Vilde 1, J J Pocidalo 1
PMCID: PMC162614  PMID: 7793882

Abstract

Several murine models have been used to evaluate the activities of antimicrobial agents against Mycobacterium avium infection. The main model used is the beige mouse model, but beige mice are expensive and not easily available. Thus, we developed a model of infection in wild C57BL/6 mice. The drugs that exhibited some activity in a previous model of early infection were evaluated in a new model of established infection. Sparfloxacin (50 mg/kg of body weight), ethambutol (50 mg/kg), minocycline (25 mg/kg), and the inhibitor of the cortisol receptors RU-40555 (100 mg/kg) were compared with clarithromycin (50 mg/kg). Treatments were started 5 weeks after the inoculation and were continued for 21 days. Sparfloxacin and RU-40555, which exhibited a moderate activity in the model of early infection, were not effective in this model of established infection. Clarithromycin and combinations with clarithromycin kept their activities against M. avium infection, both in the spleen and in lungs. The present model of established infection of normal C57BL/6 mice is more relevant than the model of early infection for a stringent evaluation of drugs.

Full Text

The Full Text of this article is available as a PDF (213.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertram M. A., Inderlied C. B., Yadegar S., Kolanoski P., Yamada J. K., Young L. S. Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis. 1986 Jul;154(1):194–195. doi: 10.1093/infdis/154.1.194. [DOI] [PubMed] [Google Scholar]
  2. Cohen Y., Perronne C., Truffot-Pernot C., Grosset J., Vilde J. L., Pocidalo J. J. Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother. 1992 Oct;36(10):2104–2107. doi: 10.1128/aac.36.10.2104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Collins F. M., Stokes R. W. Mycobacterium avium-complex infections in normal and immunodeficient mice. Tubercle. 1987 Jun;68(2):127–136. doi: 10.1016/0041-3879(87)90028-6. [DOI] [PubMed] [Google Scholar]
  4. Furney S. K., Roberts A. D., Orme I. M. Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient mice. Antimicrob Agents Chemother. 1990 Sep;34(9):1629–1632. doi: 10.1128/aac.34.9.1629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gangadharam P. R., Edwards C. K., 3rd, Murthy P. S., Pratt P. F. An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. Am Rev Respir Dis. 1983 May;127(5):648–649. doi: 10.1164/arrd.1983.127.5.648. [DOI] [PubMed] [Google Scholar]
  6. Gangadharam P. R., Perumal V. K., Jairam B. T., Rao P. N., Nguyen A. K., Farhi D. C., Iseman M. D. Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am Rev Respir Dis. 1987 Aug;136(2):329–333. doi: 10.1164/ajrccm/136.2.329. [DOI] [PubMed] [Google Scholar]
  7. Horsburgh C. R., Jr, Selik R. M. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis. 1989 Jan;139(1):4–7. doi: 10.1164/ajrccm/139.1.4. [DOI] [PubMed] [Google Scholar]
  8. Lazard T., Perronne C., Cohen Y., Grosset J., Vilde J. L., Pocidalo J. J. Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Antimicrob Agents Chemother. 1993 Apr;37(4):692–695. doi: 10.1128/aac.37.4.692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lazard T., Perronne C., Grosset J., Vilde J. L., Pocidalo J. J. Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. Antimicrob Agents Chemother. 1993 Aug;37(8):1690–1692. doi: 10.1128/aac.37.8.1690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Perronne C., Cohen Y., Truffot-Pernot C., Grosset J., Vildé J. L., Pocidalo J. J. Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice. Antimicrob Agents Chemother. 1992 Nov;36(11):2408–2412. doi: 10.1128/aac.36.11.2408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Perronne C., Gikas A., Truffot-Pernot C., Grosset J., Pocidalo J. J., Vilde J. L. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother. 1990 Aug;34(8):1508–1511. doi: 10.1128/aac.34.8.1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Perronne C., Gikas A., Truffot-Pernot C., Grosset J., Vilde J. L., Pocidalo J. J. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother. 1991 Jul;35(7):1356–1359. doi: 10.1128/aac.35.7.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Truffot-Pernot C., Ji B., Grosset J. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother. 1991 Aug;35(8):1677–1678. doi: 10.1128/aac.35.8.1677. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES